Compare FSI & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | EDSA |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 51.6M |
| IPO Year | 2000 | 2018 |
| Metric | FSI | EDSA |
|---|---|---|
| Price | $5.03 | $5.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 21.0K | ★ 53.1K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,494,325.00 | N/A |
| Revenue This Year | $63.39 | N/A |
| Revenue Next Year | $43.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.90 | $0.72 |
| 52 Week High | $11.48 | $20.32 |
| Indicator | FSI | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 29.81 | 35.78 |
| Support Level | $4.90 | $4.80 |
| Resistance Level | $5.52 | $9.00 |
| Average True Range (ATR) | 0.17 | 0.60 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 12.17 | 26.19 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.